Dr. Spigel Reflects on the PACIFIC Study in NSCLC

Video

In Partnership With:

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, reflects on the results of the PACIFIC trial in patients with non–small cell lung cancer.

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, reflects on the results of the PACIFIC trial in patients with non—small cell lung cancer (NSCLC).

Until the PACIFIC study, Spigel says that all the pivotal work over the last several years has been in the advanced stage. The PACIFIC study looked the role of immunotherapy in patients with unresectable stage III NSCLC. Findings of the study showed that durvalumab (Imfinzi) significantly improved overall survival versus placebo when used as a sequential treatment in patients with locally-advanced, unresectable NSCLC who had not progressed following standard chemoradiotherapy.

Since the discovery of concurrent chemoradiation, Spigel says that not much has been achieved by way of novel therapies for this population. This was the first time that a new therapy impacted the standard of care of chemoradiation in this setting, Spigel states.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,